Elite Pharmaceuticals (ELTP) Short Interest Ratio & Short Volume $0.42 0.00 (-0.24%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock Elite Pharmaceuticals Short Interest DataElite Pharmaceuticals (ELTP) has a short interest of 1.99 million shares, representing 0.22% of the float (the number of shares available for trading by the public). This marks a 1.02% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.7, indicating that it would take 0.7 days of the average trading volume of 947,965 shares to cover all short positions.Current Short Interest1,988,500 sharesPrevious Short Interest1,968,400 sharesChange Vs. Previous Month+1.02%Dollar Volume Sold Short$845,907.90Short Interest Ratio0.7 Days to CoverLast Record DateApril 15, 2025Outstanding Shares1,068,363,000 sharesShort Percent of Float0.22%Today's Trading Volume419,100 sharesAverage Trading Volume947,965 sharesToday's Volume Vs. Average44% Short Selling Elite Pharmaceuticals? Sign up to receive the latest short interest report for Elite Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartELTP Short Interest Over TimeELTP Days to Cover Over TimeELTP Percentage of Float Shorted Over Time Elite Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20251,988,500 shares $845,907.90 +1.0%0.2%0.7 $0.43 3/31/20251,968,400 shares $856,254.00 -0.8%0.2%1.6 $0.44 3/15/20251,984,000 shares $960,057.60 +0.1%0.2%1.7 $0.48 2/28/20251,982,000 shares $970,981.80 -5.8%0.2%1 $0.49 2/15/20252,105,000 shares $1.12 million +3.6%0.2%0.8 $0.53 1/31/20252,031,600 shares $1.02 million +3.0%N/A1.3 $0.50 1/15/20251,972,500 shares $946,800.00 -1.8%N/A0.6 $0.48 12/31/20242,008,300 shares $1.09 million -26.1%N/A0.8 $0.54 12/15/20242,717,700 shares $1.34 million +7.6%N/A0.9 $0.49 11/30/20242,526,500 shares $1.49 million +52.7%N/A0.5 $0.59 Get the Latest News and Ratings for ELTP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/20241,654,500 shares $929,001.75 +6.0%N/A0.4 $0.56 10/31/20241,560,500 shares $692,549.90 -22.1%N/A0.1 $0.44 10/15/20242,004,100 shares $883,006.46 -1.6%N/A0.6 $0.44 9/30/20242,036,000 shares $789,968.00 -7.3%N/A0.6 $0.39 9/15/20242,195,500 shares $790,599.55 +19.7%N/A0.2 $0.36 8/31/20241,834,800 shares $507,597.42 +10.5%N/A0.3 $0.28 8/15/20241,661,100 shares $317,436.21 +5.0%N/A1 $0.19 7/31/20241,581,500 shares $294,159.00 -9.2%N/A1.4 $0.19 7/15/20241,740,800 shares $330,752.00 +7.1%N/A1 $0.19 6/30/20241,625,700 shares $323,514.30 +4.8%N/A1 $0.20 6/15/20241,550,800 shares $261,092.69 -2.4%N/A2.4 $0.17 5/31/20241,588,700 shares $274,845.10 +3.8%N/A1.3 $0.17 5/15/20241,530,700 shares $214,144.93 -4.1%N/A1.3 $0.14 4/30/20241,595,900 shares $207,147.82 -0.3%N/A1.8 $0.13 4/15/20241,601,300 shares $216,175.50 +2.9%N/A1.4 $0.14 3/31/20241,555,700 shares $240,106.74 -7.7%N/A1.4 $0.15 3/15/20241,684,700 shares $234,173.30 +5.1%N/A0.9 $0.14 2/29/20241,602,900 shares $258,066.90 +0.9%N/A0.4 $0.16 2/15/20241,588,800 shares $293,769.12 +75.2%N/A0.5 $0.18 1/15/2024103,200 shares $18,008.40 +24.8%N/A0 $0.17 12/31/202382,700 shares $11,578.00 No ChangeN/A0 $0.14 11/30/202380,600 shares $11,084.11 +58.4%N/A0 $0.14 11/15/202350,900 shares $7,380.50 No ChangeN/A0 $0.15 10/15/2023228,000 shares $21,831.00 +113.5%N/A0.3 $0.10 9/30/2023106,800 shares $10,019.44 +862.2%N/A0.1 $0.09 9/15/202311,100 shares $865.80 -94.8%N/A0 $0.08 8/31/2023211,700 shares $18,629.60 +1,283.7%N/A0 $0.09 8/15/202315,300 shares $711.45 -74.6%N/A0 $0.05 7/31/202360,300 shares $2,532.60 +102.4%N/A0 $0.04 7/15/202329,800 shares $1,132.40 No ChangeN/A0 $0.04Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 6/15/202311,000 shares $374.00 -7.6%N/A0 $0.03 5/31/202311,900 shares $367.71 +643.8%N/A0 $0.03 5/15/20231,600 shares $49.44 -85.7%N/A0 $0.03 4/30/202311,200 shares $369.60 +3,633.3%N/A0 $0.03 4/15/2023300 shares $9.30 -93.6%N/A0 $0.03 3/31/20234,700 shares $136.30 +193.8%N/A0 $0.03 3/15/20231,600 shares $50.40 -20.0%N/A0 $0.03 2/28/20232,000 shares $71.20 -95.5%N/A0 $0.04 2/15/202344,200 shares $1,701.70 +44.9%N/A0.1 $0.04 1/31/202330,500 shares $1,030.90 +74.3%N/A0 $0.03 1/15/202317,500 shares $525.00 +2,087.5%N/A0 $0.03 12/30/2022800 shares $23.60 +700.0%N/A0 $0.03 12/15/2022100 shares $3.00 -99.0%N/A0 $0.03 11/30/202210,000 shares $329.00 -54.3%N/A0 $0.03 11/15/202221,900 shares $755.55 +1,268.8%N/A0.1 $0.03 10/31/20221,600 shares $57.28 -96.3%N/A0 $0.04 10/15/202242,800 shares $1,326.80 No ChangeN/A0 $0.03 9/15/2022400 shares $14.40 -99.4%N/A0 $0.04 8/31/202269,300 shares $2,477.48 -2.8%N/A0 $0.04 8/15/202271,300 shares $3,208.50 No ChangeN/A0.1 $0.05 7/15/20221,000 shares $42.90 -83.1%N/A0 $0.04 6/30/20225,900 shares $295.00 No ChangeN/A0 $0.05 5/31/20222,700 shares $123.39 No ChangeN/A0 $0.05 4/15/202216,900 shares $611.44 No ChangeN/A0 $0.04 2/28/2022212,900 shares $8,516.00 +3,030.9%N/A0.2 $0.04 2/15/20226,800 shares $289.00 -89.5%N/A0 $0.04 1/31/202264,500 shares $2,547.75 No ChangeN/A0.1 $0.04 12/31/2021100 shares $3.31 No ChangeN/A0 $0.03 12/15/2021100 shares $3.70 -99.6%N/A0 $0.04 11/30/202124,600 shares $883.14 +24,500.0%N/A0 $0.04 11/15/2021100 shares $3.82 -98.9%N/A0 $0.04 10/29/20219,400 shares $362.84 -38.2%N/A0 $0.04 10/15/202115,200 shares $608.00 +280.0%N/A0 $0.04 9/30/20214,000 shares $172.00 No ChangeN/A0 $0.04 8/31/202111,500 shares $543.95 +8.5%N/A0 $0.05 8/13/202110,600 shares $484.42 -46.7%N/A0 $0.05 7/30/202119,900 shares $953.21 +74.6%N/A0 $0.05 7/15/202111,400 shares $550.62 No ChangeN/A0 $0.05 6/15/202112,200 shares $668.56 No ChangeN/A0 $0.05 5/14/202121,600 shares $1,252.80 +151.2%N/A0 $0.06 4/30/20218,600 shares $467.41 No ChangeN/A0 $0.05 3/31/20211,500 shares $87.00 -89.2%N/A0 $0.06 3/15/202113,900 shares $847.90 -65.6%N/A0 $0.06 2/26/202140,400 shares $2,585.60 +1,054.3%N/A0 $0.06 2/12/20213,500 shares $261.80 +218.2%N/A0 $0.07 1/29/20211,100 shares $64.35 -83.3%N/A0 $0.06 12/31/202012,500 shares $675.00 No ChangeN/A0 $0.05 11/30/202027,400 shares $1,479.60 -68.4%N/A0 $0.05 11/15/202086,700 shares $6,675.90 No ChangeN/A0.1 $0.08 10/15/202012,100 shares $847.00 No ChangeN/A0 $0.07Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/31/202073,800 shares $5,830.20 +939.4%N/A0 $0.08 8/14/20207,100 shares $477.83 -92.6%N/A0 $0.07 7/31/202096,500 shares $6,031.25 +222.7%N/A0.1 $0.06 7/15/202029,900 shares $2,299.31 +121.5%N/A0 $0.08 6/30/202013,500 shares $1,120.50 -59.0%N/A0 $0.08 6/15/202032,900 shares $2,961.00 No ChangeN/A0 $0.09 5/15/202022,200 shares $1,698.30 +27.6%N/A0 $0.08 ELTP Short Interest - Frequently Asked Questions What is Elite Pharmaceuticals' current short interest? Short interest is the volume of Elite Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 1,988,500 shares of ELTP short. 0.22% of Elite Pharmaceuticals' shares are currently sold short. Learn More on Elite Pharmaceuticals' current short interest. What is a good short interest ratio for Elite Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ELTP shares currently have a short interest ratio of 1.0. Learn More on Elite Pharmaceuticals's short interest ratio. What is a good short interest percentage for Elite Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.22% of Elite Pharmaceuticals' floating shares are currently sold short. Is Elite Pharmaceuticals' short interest increasing or decreasing? Elite Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,988,500 shares, an increase of 1.0% from the previous total of 1,968,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Elite Pharmaceuticals' short interest compare to its competitors? 0.22% of Elite Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Elite Pharmaceuticals: Arcutis Biotherapeutics, Inc. (13.58%), IDEAYA Biosciences, Inc. (13.20%), Apogee Therapeutics, Inc. (25.93%), Harmony Biosciences Holdings, Inc. (7.46%), Agios Pharmaceuticals, Inc. (6.31%), Disc Medicine, Inc. (12.51%), Indivior PLC (2.18%), Edgewise Therapeutics, Inc. (17.37%), ANI Pharmaceuticals, Inc. (12.86%), Vera Therapeutics, Inc. (12.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Elite Pharmaceuticals stock? Short selling ELTP is an investing strategy that aims to generate trading profit from Elite Pharmaceuticals as its price is falling. ELTP shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Elite Pharmaceuticals? A short squeeze for Elite Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ELTP, which in turn drives the price of the stock up even further. How often is Elite Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ELTP, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Arcutis Biotherapeutics Short Interest IDEAYA Biosciences Short Interest Apogee Therapeutics Short Interest Harmony Biosciences Short Interest Agios Pharmaceuticals Short Interest Disc Medicine Short Interest Indivior Short Interest Edgewise Therapeutics Short Interest ANI Pharmaceuticals Short Interest Vera Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ELTP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.